In Chapter 9 of our series on psychedelic therapies and reimbursement, we discuss the critical challenge of ensuring equitable access. With psychedelic therapies nearing approval in Europe, disparities in access based on income, schedule flexibility, and healthcare connections are evident.

This episode highlights the underrepresentation of ethnic minorities, immigrants, and economically disadvantaged groups in clinical trials. We explore financial, cultural, and geographical barriers, examining regulatory challenges, patient selection criteria, and the need for culturally competent care.

Practical solutions, policy recommendations, and insights from experts Sergio Perez Rosal, Monnica T. Williams, and Sonya Faber are presented to promote inclusive access and address mental health disparities among marginalised populations in Europe.

(00:00) Introduction to Equitable Access in Psychedelic Therapies

(02:12) Current Disparities in Access

(03:08) Representation Issues in Clinical Trials

(04:50) Socioeconomic Barriers to Access

(06:04) Cultural and Linguistic Barriers

(07:42) Ethical Considerations in Patient Selection

(10:41) Practical Solutions and Policy Recommendations

(14:30) Focus on Marginalised Populations

(20:50) Specific Barriers and Strategies for Improvement

(29:26) Conclusion and Future Directions